“It has also lower levels of protective antibodies in the bloodstream compared with those of Moderna and Pfizer,” the online user said.noted that Brazil, one of the hardest hit by the virus, halted the clinical trial conducted by Sinovac after a “severe adverse incident” wherein a clinical trial volunteer died.
Recently, findings of its early clinical trials were published which were described by reports as “mixed.”said that the CoronaVac “generated lower levels of protective antibodies in the bloodstream compared with those arising in recovered coronavirus patients.” It also quoted an associate dean for clinical research from the University of Colorado who said that the information about CoronaVac’s antibody level was an area of “concern.”
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: